FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 360 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... March 20, 2024 Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... September 29, 2023 Sugar and cancer – what you need to know October 20, 2020 “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 Load more HOT NEWS A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... Alcohol linked to more than 740,000 new cancer cases globally in... Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... Five-Year Outcomes with CAR T Cell Therapy
